{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:01:33Z","timestamp":1787065293941,"version":"build-2736575974"},"reference-count":56,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2011,10,1]],"date-time":"2011-10-01T00:00:00Z","timestamp":1317427200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,12,7]],"date-time":"2015-12-07T00:00:00Z","timestamp":1449446400000},"content-version":"vor","delay-in-days":1528,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Kidney International"],"published-print":{"date-parts":[[2011,10]]},"DOI":"10.1038\/ki.2011.226","type":"journal-article","created":{"date-parts":[[2011,8,10]],"date-time":"2011-08-10T08:47:10Z","timestamp":1312966030000},"page":"841-850","source":"Crossref","is-referenced-by-count":68,"title":["No difference between alfacalcidol and paricalcitol in the treatment of secondary hyperparathyroidism in hemodialysis patients: a randomized crossover trial"],"prefix":"10.1016","volume":"80","author":[{"given":"Ditte","family":"Hansen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Knud","family":"Rasmussen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henning","family":"Danielsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helmut","family":"Meyer-Hofmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Egidijus","family":"Bacevicius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas G.","family":"Lauridsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens K.","family":"Madsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgitte G.","family":"Tougaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Marckmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Thye-Roenn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f8rgen E.","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svend","family":"Kreiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisbet","family":"Brandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1038\/ki.2011.226_bb0010","doi-asserted-by":"crossref","first-page":"S112","DOI":"10.1053\/ajkd.1998.v32.pm9820470","article-title":"Clinical epidemiology of cardiovascular disease in chronic renal disease","volume":"32","author":"Foley","year":"1998","journal-title":"Am J Kidney Dis"},{"key":"10.1038\/ki.2011.226_bb0015","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1056\/NEJMoa041031","article-title":"Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization","volume":"351","author":"Go","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1038\/ki.2011.226_bb0020","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1056\/NEJM200005183422003","article-title":"Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis","volume":"342","author":"Goodman","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1038\/ki.2011.226_bb0025","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1681\/ASN.2008040349","article-title":"Association of serum phosphate with vascular and valvular calcification in moderate CKD","volume":"20","author":"Adeney","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"10.1038\/ki.2011.226_bb0030","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1053\/ajkd.1998.v31.pm9531176","article-title":"Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study","volume":"31","author":"Block","year":"1998","journal-title":"Am J Kidney Dis"},{"key":"10.1038\/ki.2011.226_bb0035","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1097\/01.ASN.0000133041.27682.A2","article-title":"Mineral metabolism, mortality, and morbidity in maintenance hemodialysis","volume":"15","author":"Block","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"10.1038\/ki.2011.226_bb0040","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1681\/ASN.V12102131","article-title":"Association of elevated serum PO(4), Ca x PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients","volume":"12","author":"Ganesh","year":"2001","journal-title":"J Am Soc Nephrol"},{"key":"10.1038\/ki.2011.226_bb0045","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1681\/ASN.2004070602","article-title":"Serum phosphate levels and mortality risk among people with chronic kidney disease","volume":"16","author":"Kestenbaum","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"10.1038\/ki.2011.226_bb0050","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1053\/j.ajkd.2005.04.006","article-title":"Mild hyperphosphatemia and mortality in hemodialysis patients","volume":"46","author":"Rodriguez-Benot","year":"2005","journal-title":"Am J Kidney Dis"},{"key":"10.1038\/ki.2011.226_bb0055","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1053\/j.ajkd.2008.03.020","article-title":"Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS)","volume":"52","author":"Tentori","year":"2008","journal-title":"Am J Kidney Dis"},{"key":"10.1038\/ki.2011.226_bb0060","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1159\/000057611","article-title":"Renal osteodystrophy in predialysis and hemodialysis patients: comparison of histologic patterns and diagnostic predictivity of intact PTH","volume":"91","author":"Coen","year":"2002","journal-title":"Nephron"},{"key":"10.1038\/ki.2011.226_bb0065","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/0272-6386(95)90453-0","article-title":"Relationship between intact 1-84 parathyroid hormone and bone histomorphometric parameters in dialysis patients without aluminum toxicity","volume":"26","author":"Wang","year":"1995","journal-title":"Am J Kidney Dis"},{"key":"10.1038\/ki.2011.226_bb0070","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1038\/sj.ki.5001754","article-title":"Incidence and risk factors for hip or other bone fractures among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study","volume":"70","author":"Jadoul","year":"2006","journal-title":"Kidney Int"},{"key":"10.1038\/ki.2011.226_bb0075","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1097\/01.ASN.0000133041.27682.A2","article-title":"Mineral metabolism, mortality, and morbidity in maintenance hemodialysis","volume":"15","author":"Block","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"10.1038\/ki.2011.226_bb0080","doi-asserted-by":"crossref","first-page":"F8","DOI":"10.1152\/ajprenal.00336.2004","article-title":"Vitamin D","volume":"289","author":"Dusso","year":"2005","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1038\/ki.2011.226_bb0085","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/0272-6386(95)90455-7","article-title":"A new analog of calcitriol, 19-nor-1,25-(OH)2D2, suppresses parathyroid hormone secretion in uremic rats in the absence of hypercalcemia","volume":"26","author":"Slatopolsky","year":"1995","journal-title":"Am J Kidney Dis"},{"key":"10.1038\/ki.2011.226_bb0090","series-title":"Cochrane Database Syst Rev","first-page":"CD005633","article-title":"Vitamin D compounds for people with chronic kidney disease requiring dialysis","author":"Palmer","year":"2009"},{"key":"10.1038\/ki.2011.226_bb0095","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1067\/mlc.2002.122819","article-title":"Differential effects of 19-nor-1,25-dihydroxyvitamin D(2) and 1,25-dihydroxyvitamin D(3) on intestinal calcium and phosphate transport","volume":"139","author":"Brown","year":"2002","journal-title":"J Lab Clin Med"},{"key":"10.1038\/ki.2011.226_bb0100","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1681\/ASN.V105980","article-title":"Differential effects of 1,25-dihydroxy-vitamin D3 and 19-nor-1,25-dihydroxy-vitamin D2 on calcium and phosphorus resorption in bone","volume":"10","author":"Finch","year":"1999","journal-title":"J Am Soc Nephrol"},{"key":"10.1038\/ki.2011.226_bb0105","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1111\/j.1440-1797.2008.01058.x","article-title":"Intravenous calcitriol versus paricalcitol in haemodialysis patients with severe secondary hyperparathyroidism","volume":"14","author":"Abdul Gafor","year":"2009","journal-title":"Nephrology (Carlton)"},{"key":"10.1038\/ki.2011.226_bb0110","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1053\/ajkd.2002.36899","article-title":"Differential effects of acute administration of 19-Nor-1,25-dihydroxy-vitamin D2 and 1,25-dihydroxy-vitamin D3 on serum calcium and phosphorus in hemodialysis patients","volume":"40","author":"Coyne","year":"2002","journal-title":"Am J Kidney Dis"},{"key":"10.1038\/ki.2011.226_bb0115","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1053\/ajkd.2001.28114","article-title":"Paricalcitol in dialysis patients with calcitriol-resistant secondary hyperparathyroidism","volume":"38","author":"Llach","year":"2001","journal-title":"Am J Kidney Dis"},{"key":"10.1038\/ki.2011.226_bb0120","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1159\/000266204","article-title":"Differential effects of paricalcitol and calcitriol on intestinal calcium absorption in hemodialysis patients","volume":"31","author":"Lund","year":"2010","journal-title":"Am J Nephrol"},{"key":"10.1038\/ki.2011.226_bb0125","doi-asserted-by":"crossref","first-page":"S61","DOI":"10.1053\/ajkd.1998.v32.pm9808145","article-title":"Therapy of secondary hyperparathyroidism with 19-nor-1alpha,25-dihydroxyvitamin D2","volume":"32","author":"Martin","year":"1998","journal-title":"Am J Kidney Dis"},{"key":"10.1038\/ki.2011.226_bb0130","series-title":"Kidney Int Suppl","first-page":"S33","article-title":"Treatment of secondary hyperparathyroidism in ESRD: a 2-year, single-center crossover study","author":"Mittman","year":"2010"},{"key":"10.1038\/ki.2011.226_bb0135","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.2215\/CJN.03461006","article-title":"Opposite effects of calcitriol and paricalcitol on the parathyroid hormone-(1-84)\/large carboxy-terminal-parathyroid hormone fragments ratio in patients with stage 5 chronic kidney disease","volume":"2","author":"Monier-Faugere","year":"2007","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1038\/ki.2011.226_bb0140","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1007\/s00467-006-0204-5","article-title":"Paricalcitol versus calcitriol treatment for hyperparathyroidism in pediatric hemodialysis patients","volume":"21","author":"Seeherunvong","year":"2006","journal-title":"Pediatr Nephrol"},{"key":"10.1038\/ki.2011.226_bb0145","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1046\/j.1523-1755.2003.00878.x","article-title":"Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism","volume":"63","author":"Sprague","year":"2003","journal-title":"Kidney Int"},{"key":"10.1038\/ki.2011.226_bb0150","doi-asserted-by":"crossref","first-page":"S51","DOI":"10.1053\/ajkd.2001.28110","article-title":"Suppression of parathyroid hormone secretion in hemodialysis patients: comparison of paricalcitol with calcitriol","volume":"38","author":"Sprague","year":"2001","journal-title":"Am J Kidney Dis"},{"key":"10.1038\/ki.2011.226_bb0155","series-title":"Hemodial Int","article-title":"Switch from calcitriol to paricalcitol in secondary hyperparathyroidism of hemodialysis patients: responsiveness is related to parathyroid gland size","author":"Vulpio","year":"2011"},{"key":"10.1038\/ki.2011.226_bb0160","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/0304-4165(85)90168-0","article-title":"25-Hydroxylation of 1 alpha-hydroxyvitamin D-3 in rat and human liver","volume":"840","author":"Saarem","year":"1985","journal-title":"Biochim Biophys Acta"},{"key":"10.1038\/ki.2011.226_bb0165","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1093\/ndt\/17.5.829","article-title":"Pharmacokinetics of 1,25(OH)(2)D(3) and 1alpha(OH)D(3) in normal and uraemic men","volume":"17","author":"Brandi","year":"2002","journal-title":"Nephrol Dial Transplant"},{"key":"10.1038\/ki.2011.226_bb0170","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1093\/ndt\/gfi186","article-title":"The vitamin D prodrugs 1alpha(OH)D2, 1alpha(OH)D3 and BCI-210 suppress PTH secretion by bovine parathyroid cells","volume":"21","author":"Brown","year":"2006","journal-title":"Nephrol Dial Transplant"},{"key":"10.1038\/ki.2011.226_bb0175","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1159\/000169179","article-title":"Comparison of the efficacy of two injectable forms of vitamin D3 and oral one-alpha in treatment of secondary hyperparathyroidism in patients on maintenance hemodialysis","volume":"17","author":"el-Reshaid","year":"1997","journal-title":"Am J Nephrol"},{"key":"10.1038\/ki.2011.226_bb0180","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1111\/j.1440-1797.2010.01398.x","article-title":"Randomized trial comparing pulse calcitriol and alfacalcidol for the treatment of secondary hyperparathyroidism in haemodialysis patients","volume":"16","author":"Kiattisunthorn","year":"2011","journal-title":"Nephrology (Carlton)"},{"key":"10.1038\/ki.2011.226_rf0185","first-page":"e36","article-title":"Oral calcitriol versus oral alfacalcidol for the treatment of secondary hyperparathyroidism in patients receiving hemodialysis: a randomized, crossover trial","volume":"15","author":"Moe","year":"2008","journal-title":"Can J Clin Pharmacol"},{"key":"10.1038\/ki.2011.226_bb0190","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1053\/j.ajkd.2005.10.007","article-title":"Paricalcitol capsule for the treatment of secondary hyperparathyroidism in stages 3 and 4 CKD","volume":"47","author":"Coyne","year":"2006","journal-title":"Am J Kidney Dis"},{"key":"10.1038\/ki.2011.226_bb0195","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1053\/ajkd.1998.v32.pm9708607","article-title":"Controlled trial of falecalcitriol versus alfacalcidol in suppression of parathyroid hormone in hemodialysis patients with secondary hyperparathyroidism","volume":"32","author":"Akiba","year":"1998","journal-title":"Am J Kidney Dis"},{"key":"10.1038\/ki.2011.226_bb0200","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1053\/j.ajkd.2007.03.008","article-title":"Intravenous paricalcitol for treatment of secondary hyperparathyroidism in children on hemodialysis","volume":"49","author":"Greenbaum","year":"2007","journal-title":"Am J Kidney Dis"},{"key":"10.1038\/ki.2011.226_bb0205","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/ki.2010.352","article-title":"Calcitriol and doxercalciferol are equivalent in controlling bone turnover, suppressing parathyroid hormone, and increasing fibroblast growth factor-23 in secondary hyperparathyroidism","volume":"79","author":"Wesseling-Perry","year":"2011","journal-title":"Kidney Int"},{"key":"10.1038\/ki.2011.226_bb0210","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1359\/JBMR.0301264","article-title":"FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis","volume":"19","author":"Shimada","year":"2004","journal-title":"J Bone Miner Res"},{"key":"10.1038\/ki.2011.226_bb0215","first-page":"4003","article-title":"The parathyroid is a target organ for FGF23 in rats","volume":"117","author":"Ben-Dov","year":"2007","journal-title":"J Clin Invest"},{"key":"10.1038\/ki.2011.226_bb0220","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1677\/JOE-07-0267","article-title":"Fibroblast growth factor-23 regulates parathyroid hormone and 1alpha-hydroxylase expression in cultured bovine parathyroid cells","volume":"195","author":"Krajisnik","year":"2007","journal-title":"J Endocrinol"},{"key":"10.1038\/ki.2011.226_bb0225","first-page":"200","article-title":"Structure-function relationships in the vitamin D endocrine system","volume":"16","author":"Bouillon","year":"1995","journal-title":"Endocr Rev"},{"key":"10.1038\/ki.2011.226_bb0230","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0272-6386(97)90571-0","article-title":"A new analog of 1,25-(OH)2D3, 19-NOR-1,25-(OH)2D2, suppresses serum PTH and parathyroid gland growth in uremic rats without elevation of intestinal vitamin D receptor content","volume":"30","author":"Takahashi","year":"1997","journal-title":"Am J Kidney Dis"},{"key":"10.1038\/ki.2011.226_bb0235","series-title":"The Spectrum of Mineral and Bone Disorders in Chronic Kidney Disease","first-page":"417","article-title":"New vitamin D analogs for chronic kidney disease patients","author":"Dusso","year":"2010"},{"key":"10.1038\/ki.2011.226_bb0240","doi-asserted-by":"crossref","first-page":"16754","DOI":"10.1074\/jbc.M310271200","article-title":"Inactivation of the 25-hydroxyvitamin D 1alpha-hydroxylase and vitamin D receptor demonstrates independent and interdependent effects of calcium and vitamin D on skeletal and mineral homeostasis","volume":"279","author":"Panda","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1038\/ki.2011.226_bb0245","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.1053\/ajkd.2001.28112","article-title":"Paricalcitol dosing according to body weight or severity of hyperparathyroidism: a double-blind, multicenter, randomized study","volume":"38","author":"Martin","year":"2001","journal-title":"Am J Kidney Dis"},{"key":"10.1038\/ki.2011.226_bb0250","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1038\/sj.ki.5001514","article-title":"Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients","volume":"70","author":"Kalantar-Zadeh","year":"2006","journal-title":"Kidney Int"},{"key":"10.1038\/ki.2011.226_bb0255","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.2215\/CJN.01760408","article-title":"Ratio of paricalcitol dosage to serum parathyroid hormone level and survival in maintenance hemodialysis patients","volume":"3","author":"Shinaberger","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1038\/ki.2011.226_bb0260","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1159\/000168465","article-title":"Long-term suppression of secondary hyperparathyroidism by intravenous 1 alpha-hydroxyvitamin D3 in patients on chronic hemodialysis","volume":"12","author":"Brandi","year":"1992","journal-title":"Am J Nephrol"},{"key":"10.1038\/ki.2011.226_bb0265","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1046\/j.1525-139X.2002.00086.x","article-title":"Comparative review of the pharmacokinetics of vitamin D analogues","volume":"15","author":"Bailie","year":"2002","journal-title":"Semin Dial"},{"key":"10.1038\/ki.2011.226_bb0270","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1210\/endo.136.4.7895652","article-title":"The roles of calcium and 1,25-dihydroxyvitamin D3 in the regulation of vitamin D receptor expression by rat parathyroid glands","volume":"136","author":"Brown","year":"1995","journal-title":"Endocrinology"},{"key":"10.1038\/ki.2011.226_bb0275","doi-asserted-by":"crossref","first-page":"20082","DOI":"10.1016\/S0021-9258(19)88668-4","article-title":"Up-regulation of the vitamin D receptor in response to 1,25-dihydroxyvitamin D3 results from ligand-induced stabilization","volume":"267","author":"Wiese","year":"1992","journal-title":"J Biol Chem"},{"key":"10.1038\/ki.2011.226_bb0280","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/1471-2369-10-28","article-title":"Treatment of secondary hyperparathyroidism in haemodialysis patients: a randomised clinical trial comparing paricalcitol and alfacalcidol","volume":"10","author":"Hansen","year":"2009","journal-title":"BMC Nephrol"},{"key":"10.1038\/ki.2011.226_bb0285","series-title":"Practical Statistics for Medical Research","author":"Altman","year":"1991"}],"container-title":["Kidney International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253815551429?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253815551429?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,11,29]],"date-time":"2021-11-29T23:01:06Z","timestamp":1638226866000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0085253815551429"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10]]},"references-count":56,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2011,10]]}},"alternative-id":["S0085253815551429"],"URL":"https:\/\/doi.org\/10.1038\/ki.2011.226","relation":{},"ISSN":["0085-2538"],"issn-type":[{"value":"0085-2538","type":"print"}],"subject":[],"published":{"date-parts":[[2011,10]]}}}